3rd Annual Pharmaceutical Compliance Congress Canada

June 11-12, 2019 | Canada

CBI’s 3rd Annual Pharmaceutical Compliance Congress Canadaconvenes top Canadian compliance practitioners and leading experts to discuss effective strategies to achieve organization-wide compliance, from the compliance and legal teams to the oversight of the promotional marketing and sales teams. Join your Canadian colleagues for robust conversations on the top issues facing industry today.

Spotlight

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dollars. Pharmaceutical companies, biotech firms and anyone in the business of developing new therapeutics knows there is significant pressure to reduce the cost of R&D, while still delivering safe and effective treatments that alleviate symptoms or cure a medical condition.


OTHER PAST CONFERENCES

IDN & Bio/Pharma Partnering Summit

August 16-17, 2022 | USA

A think-tank for industry pioneers, showcasing novel case studies and innovative partnership models that deliver enhanced value, manage costs and improve quality

World Drug Safety Congress Europe

September 27-29, 2022 | USA

The World Drug Safety Congress Europe is empowering patients, physicians, pharma, biotech and consumers to make the best drug safety decisions.

19th Annual Pharma Data Congress

September 8-9, 2022 | UK

Showcasing success in FAIR data implementation, data analytics in drug discovery, AI/ML technologies, RWE management, data storage & infrastructure, multi-omic data integration and management

Temperature Controlled Logistics And Security

September 20-22, 2022 | USA

We are the world’s most innovative and educational event covering all you need to know about optimizing your end-to-end supply chain from a patient-centric, regulatory-compliant and cost effective perspective.

Spotlight

Over the years, studies have been conducted to ascertain the cost of research and development (“R&D”) required to bring a new drug to market. Experts disagree on the exact amount, but the consensus is that the figure is in the hundreds of millions to over a billion dollars. Pharmaceutical companies, biotech firms and anyone in the business of developing new therapeutics knows there is significant pressure to reduce the cost of R&D, while still delivering safe and effective treatments that alleviate symptoms or cure a medical condition.

resources